Overview

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Status:
RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Phase:

PHASE1

Details

Lead Sponsor:

BeiGene

Treatments:

zanubrutinib